Integration of new capabilities to strengthen the offer and to increase the revenue of the group Oncodesign service
Download the free guide
Boost your gains
Adding complementary expertise in immunology and infectious diseases
Bertin Pharma is a subsidiary of Bertin Technologies, an entity of the group CNIM
Dijon, May 10, 2017 – ONCODESIGN (FR0011766229 – ALONC), a biotechnology company serving the pharmaceutical industry for the discovery of new therapeutic molecules against cancer and other serious illnesses without a known effective treatment, announces be entered in a phase of exclusive negotiations for the acquisition of service activities in Metabolism, Pharmaco-kinetics, Bioanalysis and Translational Medicine of Bertin Pharma. These activities in the fields of immunology and infectious diseases, would ideally complements the current offer of services of the group Oncodesign.
The areas in question account for about 48 employees, for a turnover of 5.3 M in 2016. It exhibits many complementarities between technological and regulatory with Oncodesign, and would contribute to the acceleration of the group’s strategic plan Oncodesign in-services activities for the period 2017-2020.
This project, which is the subject of a procedure of information and consultation of staff representative bodies concerned, could be finalized during the summer of 2017. At this stage, there is no certainty that agreement will be reached or that the transaction will be finalized. No further comment will be provided until the conclusion of an agreement.
Download the free guide
Boost your gains
